Search

Displaying results 1011 - 1020 of 7536 in total
  1. Drug

    Tetrofosmin

    go.drugbank.com/drugs/DB11180
    Approved

    Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.

  2. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  3. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    It was approved by the FDA in 1980, but has since been discontinued. … Refer to these drug entries for more information.

  4. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. … [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875.

  5. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … action on the bile ducts and gallbladder.

  6. Drug

    Homatropine methylbromide

    go.drugbank.com/drugs/DB00725
    Approved

    It may also be used to prevent nausea, vomiting, and motion sickness. … Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.

    Mixtures: BONESPAS GOTAS COMPOSITE NF
  7. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver. … [A264833] On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of non-small cell lung cancer and pancreatic adenocarcinoma.

  8. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    by an FDA-approved test [L2939]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

  9. Drug

    Piperonyl butoxide

    go.drugbank.com/drugs/DB09350
    ApprovedVet approved

    It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.

  10. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. … [L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for